The Centre for Medicines Discovery at the University of Oxford and BPGbio, an artificial intelligence (AI)-focused biopharmaceutical company, established a five-year research collaboration that aims to advance new technologies for treatments for people with brain diseases like Parkinson’s who have limited options. Together the partners will validate and…
Gain Therapeutics has presented new preclinical data showing GT-02287, its experimental therapy for Parkinson’s disease, can slow disease progression in mouse and cellular models of the disease. Overall, the treatment was shown to improve motor function and coordination, and activities of daily living in mouse models of Parkinson’s…
A single dose of CAP-003, a gene therapy being developed by Capsida Biotherapeutic, significantly increased the levels of GCase enzyme in the brains of non-human primates. The enzyme levels reached up to eight times the amount considered necessary to restore normal enzyme activity in individuals with Parkinson’s disease…
Researchers at New York University (NYU) Langone Health were awarded a two-year, $1.6 million grant by the National Institutes of Health (NIH) to investigate eye changes as potential early signs and progression markers of Parkinson’s disease and Alzheimer’s. The grant, given under the NIH Common Fund Venture Program’s…
Irlab Therapeutics’ oral therapy IRL757 was safe and well tolerated in healthy volunteers in the first part of a Phase 1 study testing the therapy, a potential treatment for apathy in patients with Parkinson’s disease and other neurological conditions. “This bodes well for the further clinical development of a…
Two studies support the safety and tolerability of Nuplazid (pimavanserin) in older or frail adults with psychosis associated with Parkinson’s disease. Safety data on Nuplazid, the only medication approved by the U.S. Food and Drug Administration (FDA) to treat Parkinson’s-associated psychosis, were presented at this year’s International…
Aspen Neuroscience has opened a manufacturing facility for ANPD001, its investigational stem cell therapy for Parkinson’s disease being used in an ongoing Phase 1/2a clinical trial. The 22,000-square-foot facility is an expansion of the company’s headquarters near San Diego, and is reported to include three manufacturing suites certified…
App-based consumer technology like Rune Labs’ StrivePD may help people with Parkinson’s disease feel more confident in managing their symptoms, bridging the gap in specialty care by providing continuous monitoring, according to the results of a pilot program done in collaboration with Kaiser Permanente. Patients in the program…
Changes in the levels of thyroid hormones in the bloodstream are related to cognitive impairments in people with Parkinson’s disease, according to a new study by researchers in China. “Our findings provided definite proof that changes in thyroid hormone levels have clinical implications for cognitive outcomes” in Parkinson’s,…
Exposure to air pollutants, such as fine particulate matter and nitrogen dioxide, may increase the risk of developing Parkinson’s disease and dyskinesia, or involuntary movements, according to a study using data from the Rochester Epidemiology Project. These findings add to growing evidence that breathing polluted air is a…
Get regular updates to your inbox.